Home » Newsletters » The Carlat Addiction Treatment Report

The Carlat Addiction Treatment Report

Stimulants (October/November/December) | 2024

View Archived Issues

Learning Objectives, Stimulants, CATR, October/November/December 2024

October 1, 2024

After reading these articles, you should be able to…

Overview of Stimulants

October 1, 2024

Michael Weaver, MD, FASAM and Noah Capurso, MD

This article offers an insightful overview of the pharmacology of various stimulant drugs, their potential for misuse, and the dangers they pose—especially with rising overdose rates due to contamination with fentanyl. Learn about the history, various classes of stimulants, and the treatments available for stimulant use disorder, as well as the crucial harm reduction strategies aimed at minimizing risks.

Update on Stimulant Use Disorder

October 1, 2024

Brian Hurley, MD, MBA, FAPA, DFASAM

The interview with Dr. Hurley provides crucial insights into the world of psychostimulants, their misuse, and the emerging Fourth Wave of the Overdose Epidemic. Dr. Hurley discusses everything from the differences between stimulants like methamphetamine and cocaine to the importance of harm reduction strategies and evidence-based treatments for stimulant use disorder.

Contingency Management for Stimulant Use Disorder

October 1, 2024

Dominick DePhilippis, PhD

Contingency management (CM) is a clinical approach that leverages principles of operant conditioning to treat stimulant use disorder. In this interview, Dr. DePhilippis explains how CM incentivizes recovery behaviors like abstinence with immediate rewards, making it an effective treatment tool. Learn how this evidence-based strategy works, why it’s considered the gold standard for treating stimulant use disorder, and the challenges of implementing CM in real-world settings.

Boost or Bust: Navigating the Risks of Prescription Stimulants

October 1, 2024

David Stiffler, MD and Noah Capurso, MD

Prescription stimulants, while effective for treating ADHD, are widely taken without a prescription, particularly by young adults for cognitive enhancement, weight loss, and recreational purposes. This misuse poses serious risks, from developing stimulant use disorder to experiencing severe cardiovascular and psychiatric effects. In this article, you'll learn about the prevalence and patterns of stimulant misuse, its associated dangers, and tips on how to manage it in clinical practice.

Rapid Initiation of Extended-Release Buprenorphine

October 1, 2024

Aniruddha Deka, MD

Long-acting buprenorphine is a promising new treatment for opioid use disorder, but it usually requires a seven-day stabilization period before initiation. Here, researchers develop and evaluate a novel protocol for initiating long-acting injectable buprenorphine in a single day. The trial is small, but results are promising.

How Do We Help Depressed Smokers Quit?

October 1, 2024

Justin Morales, MD and Deepti Anbarasan, MD

Tobacco smoking and major depression are highly comorbid, and depressed patients usually have a tougher time quitting than their non-depressed counterparts. In this research study, investigators compared the efficacy of anti-smoking medications in those with depression. The results may surprise you.

Erratum

October 1, 2024

CME Post-Test, Stimulants, CATR, October/November/December 2024

October 1, 2024

By successfully completing the test you will be awarded a certificate for 2 CME credit.

Treating Opioid Use Disorder—A Fact Book (2024)
All the tools you need to assess and treat patients struggling with opioid use disorder.
READ MORE

General Psychiatry
KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything
Read More

General Psychiatry
A Scam for Every Woman, Child, and Man: Part 2
1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
Listen now